Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?

被引：6

作者：

Song, Fei ^{[1
]}

Tarantino, Paolo ^{[2
,3
,4
]}

Garrido-Castro, Ana ^{[2
,3
]}

Lynce, Filipa ^{[2
,3
]}

Tolaney, Sara M. ^{[2
,3
]}

Schlam, Ilana ^{[1
,5
]}

机构：

[1] Tufts Med Ctr, Div Hematol & Oncol, Boston, MA 02111 USA

[2] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA USA

[3] Harvard Med Sch, Boston, MA USA

[4] Univ Milan, Dept Oncol & Onco Hematol, Milan, Italy

[5] Tufts Univ, Boston, MA 02155 USA

来源：

CURRENT ONCOLOGY REPORTS | 2024年 / 26卷 / 01期

关键词：

Adjuvant therapy; Early breast cancer; Immunotherapy; Neoadjuvant chemotherapy; Triple negative breast cancer; STANDARD NEOADJUVANT CHEMOTHERAPY; PHASE-III; ADJUVANT; PEMBROLIZUMAB; CARBOPLATIN; EXPRESSION; EFFICACY; SURVIVAL; THERAPY; BURDEN;

D O I：

10.1007/s11912-023-01487-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of ReviewIn this narrative review, we discuss the optimal timing of immune checkpoint inhibitors (ICI) in early triple negative breast cancer (TNBC), the landscape of predictive biomarkers for the use of immunotherapy, and the mounting literature suggesting a benefit for an early use of ICI.Recent FindingsTNBC is associated with a poor prognosis relative to other breast cancer subtypes, and until recently, the treatment of TNBC was limited to cytotoxic chemotherapy. In 2021, the immune-checkpoint inhibitor, pembrolizumab, was approved in combination with neoadjuvant chemotherapy for patients with high-risk early stage TNBC. This approval changed the treatment paradigm of early TNBC concomitantly raised several challenges in clinical practice, pertaining to patient selection, toxicity management, and post-neoadjuvant treatment, among others.SummaryThe introduction of neoadjuvant chemoimmunotherapy has transformed the treatment landscape for early TNBC. However, several challenges, including patient selection, toxicity management, and the identification of predictive biomarkers, need to be addressed. Future research should focus on refining the timing and duration of immunotherapy, optimizing the chemotherapy partner, and exploring novel predictive biomarkers of response or toxicity.

引用

页码：21 / 33

页数：13

共 85 条

[1] LYMPHOCYTE INFILTRATES AS A PROGNOSTIC VARIABLE IN FEMALE BREAST-CANCER [J].

AALTOMAA, S ;

LIPPONEN, P ;

ESKELINEN, M ;

KOSMA, VM ;

MARIN, S ;

ALHAVA, E ;

SYRJANEN, K .

EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) :859-864

[2]

Akers R., 2023, ESMO BREAST CANC C

[3] Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials [J].

Alberro, J. A. ;

Ballester, B. ;

Deulofeu, P. ;

Fabregas, R. ;

Fraile, M. ;

Gubern, J. M. ;

Janer, J. ;

Moral, A. ;

de Pablo, J. L. ;

Penalva, G. ;

Puig, P. ;

Ramos, M. ;

Rojo, R. ;

Santesteban, P. ;

Serra, C. ;

Sola, M. ;

Solarnau, L. ;

Solsona, J. ;

Veloso, E. ;

Vidal, S. ;

Abe, O. ;

Abe, R. ;

Enomoto, K. ;

Kikuchi, K. ;

Koyama, H. ;

Masuda, H. ;

Nomura, Y. ;

Ohashi, Y. ;

Sakai, K. ;

Sugimachi, K. ;

Toi, M. ;

Tominaga, T. ;

Uchino, J. ;

Yoshida, M. ;

Coles, C. E. ;

Haybittle, J. L. ;

Moebus, V. ;

Leonard, C. F. ;

Calais, G. ;

Garaud, P. ;

Collett, V. ;

Davies, C. ;

Delmestri, A. ;

Sayer, J. ;

Harvey, V. J. ;

Holdaway, I. M. ;

Kay, R. G. ;

Mason, B. H. ;

Forbe, J. F. ;

Franci, P. A. .

LANCET ONCOLOGY, 2018, 19 (01) :27-39

[4] Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche [J].

Baldominos, Pilar ;

Barbera-Mourelle, Alex ;

Barreiro, Olga ;

Huang, Yu ;

Wight, Andrew ;

Cho, Jae-Won ;

Zhao, Xi ;

Estivill, Guillem ;

Adam, Isam ;

Sanchez, Xavier ;

McCarthy, Shannon ;

Schaller, Julien ;

Khan, Zara ;

Ruzo, Albert ;

Pastorello, Ricardo ;

Richardson, Edward T. ;

Dillon, Deborah ;

Montero-Llopis, Paula ;

Barroso-Sousa, Romualdo ;

Forman, Juliet ;

Shukla, Sachet A. ;

Tolaney, Sara M. ;

Mittendorf, Elizabeth A. ;

von Andrian, Ulrich H. ;

Wucherpfennig, Kai W. ;

Hemberg, Martin ;

Agudo, Judith .

CELL, 2022, 185 (10) :1694-+

[5] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Hurvitz, S. A. ;

Tolaney, S. M. ;

Loirat, D. ;

Punie, K. ;

Oliveira, M. ;

Brufsky, A. ;

Sardesai, S. D. ;

Kalinsky, K. ;

Zelnak, A. B. ;

Weaver, R. ;

Traina, T. ;

Dalenc, F. ;

Aftimos, P. ;

Lynce, F. ;

Diab, S. ;

Cortes, J. ;

O'Shaughnessy, J. ;

Dieras, V ;

Ferrario, C. ;

Schmid, P. ;

Carey, L. A. ;

Gianni, L. ;

Piccart, M. J. ;

Loibl, S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. S. ;

Itri, L. M. ;

Rugo, H. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541

[6]

Barrios C.H., 2023, Ann Oncol, V8, DOI [10.1016/esmoop/esmoop101220, DOI 10.1016/J.ESMOOP.2023.101571, 10.1016/j.esmoop.2023.101571]

[7] Prevalence and mutational determinants of high tumor mutation burden in breast cancer [J].

Barroso-Sousa, R. ;

Jain, E. ;

Cohen, O. ;

Kim, D. ;

Buendia-Buendia, J. ;

Winer, E. ;

Lin, N. ;

Tolaney, S. M. ;

Wagle, N. .

ANNALS OF ONCOLOGY, 2020, 31 (03) :387-394

[8] Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC) [J].

Barroso-Sousa, Romualdo ;

Li, Tianyu ;

Reddy, Sangeetha ;

Emens, Leisha A. ;

Overmoyer, Beth ;

Lange, Paulina ;

Dilullo, Molly K. ;

Attaya, Victoria ;

Kimmel, Jeffrey ;

Winer, Eric P. ;

Mittendorf, Elizabeth A. ;

Tayob, Nabihah ;

Tolaney, Sara M. .

CANCER RESEARCH, 2022, 82 (04)

[9] Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial [J].

Bianchini, Giampaolo ;

Wang, Xiao Qian ;

Danenberg, Esther ;

Huang, Chiun-Sheng ;

Egle, Daniel ;

Callari, Maurizio ;

Bermejo, Begona ;

Zamagni, Claudio ;

Thill, Marc ;

Anton, Anton ;

Dugo, Matteo ;

Zambelli, Stefania ;

Russo, Stefania ;

Ciruelos, Eva Maria ;

Greil, Richard ;

Semiglazov, Vladimir ;

Colleoni, Marco ;

Kelly, Catherine ;

Mariani, Gabriella ;

Del Mastro, Lucia ;

Gyorffy, Balazs ;

Biasi, Olivia ;

Valagussa, Pinuccia ;

Viale, Giuseppe ;

Gianni, Luca ;

Ali, H. Raza .

CANCER RESEARCH, 2022, 82 (04)

[10] Treatment landscape of triple-negative breast cancer - expanded options, evolving needs [J].

Bianchini, Giampaolo ;

De Angelis, Carmine ;

Licata, Luca ;

Gianni, Luca .

NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (02) :91-113

← 1 2 3 4 5 6 7 8 9 →